Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 1/20 | 0.76 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853024 | 0.87 | P2RY6 (1.00) | P2RY6MIFCA1CA2CYP2A6 | |
| SCHEMBL9547715 | 0.87 | P2RY6 (1.00) | P2RY6MIFCA1CA2CYP2A6 | |
| SCHEMBL16192966 | 0.83 | P2RY6 (0.68) | P2RY6NOS3NOS1NOS2MIF | |
| SCHEMBL347652 | 0.81 | P2RY6 (0.79) | P2RY6MIFCA1CA2CYP2A6 | |
| SCHEMBL6417472 | 0.79 | P2RY6 (0.76) | P2RY6MIFCA1CA2CYP2A6 | |
| SCHEMBL8503279 | 0.79 | P2RY6 (0.76) | P2RY6MIFCA1CA2CYP2A6 | |
| SCHEMBL5186242 | 0.79 | P2RY6 (0.76) | P2RY6MIFCA1CA2CYP1A2 | |
| SCHEMBL27467439 | 0.79 | P2RY6 (0.76) | P2RY6MIFCA1CA2CYP2A6 | |
| SCHEMBL1193625 | 0.78 | P2RY6 (0.74) | P2RY6MIFCA1CA2CYP1A2 | |
| SCHEMBL9547731 | 0.78 | P2RY6 (0.74) | P2RY6MIFCA1CA2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-1476197-B1 | SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE | CA NAT RESEARCH COUNCIL (CA) | 2009-01-07 | — | — | EP | disclosed |
| EP-1129092-B1 | PORPHYRIN COMPOUNDS, THEIR CONJUGATES AND ASSAY METHODS BASED ON THE USE OF SAID CONJUGATES | ARCTIC DIAGNOSTICS OY (FI) | 2005-02-23 | — | — | EP | disclosed |
| US-6740756-B1 | POLYAMINO-POLYCARBOXYLIC ACID DERIVATIVES CONTAINING FUSED HETEROCYCLIC KETONE SUBSTITUTED FUNCTIONALITY; LONG LIVED ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-6582930-B1 | Porphyrin for use as diagnostic tools in the food industry and pollution control | ARCTIC DIAGNOSTICS OY (FI) | 2003-06-24 | — | — | US | disclosed |
| EP-1095011-A4 | NOVEL FLUORESCENT LANTHANIDE CHELATES | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1129092-A1 | PORPHYRIN COMPOUNDS, THEIR CONJUGATES AND ASSAY METHODS BASED ON THE USE OF SAID CONJUGATES | Arctic Diagnostics OY (FI) | 2001-09-05 | — | — | EP | disclosed |
| EP-1095011-A1 | NOVEL FLUORESCENT LANTHANIDE CHELATES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000027847-A1 | PORPHYRIN COMPOUNDS, THEIR CONJUGATES AND ASSAY METHODS BASED ON THE USE OF SAID CONJUGATES | ARCTIC DIAGNOSTICS OY (FI) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000001663-A1 | NOVEL FLUORESCENT LANTHANIDE CHELATES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | P2RY6 4603/4885NOS3 1837/4885NOS1 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.